The primary objective of this study is to evaluate the effect of Beclomethasone dipropionate HFA on small airways compared to Fluticasone propionate powder for inhalation administered twice daily to poorly controlled asthmatics.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
49
Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
National Jewish Medical and Research Center
Denver, Colorado, United States
Change in post-inhalation percent-predicted FEF 25-75 (%) from baseline (week 0) to week 12
Time frame: Final Visit
Mean and mean change from pre-dose to 15-minute post-dose in percent predicted FEV1 (%) at week 12
Time frame: week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.